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Exosomes are part of the large heterogeneous group of extracellular vesicles (EV’s) which 
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1 Introduction 
 
Breast cancer is the most common cancer type among women in industrialized coun-
tries (Puistola 2011). In the year 2011 31.8% of all the cancers diagnosed in Finnish 
women were breast cancer (Suomen Syöpärekisteri 2011). There has been a notable 
increase of breast cancer cases in the recent years. A part is explained by the aging 
effect of the main population, but it is thought that around 2/3 is explained by other fac-
tors. (Puistola 2011.)  
 
Breast cancer is treated with a combination of surgical removal of the tumor, radiother-
apy, chemotherapy and hormonal treatment. In cases of HER2 positive breast cancer 
trastuzumab is used with chemotherapy. (Puistola 2011.) 
 
Trastuzumab emtansine (T-DM1) has been approved recently for the treatment of 
HER2-positive metastatic cancer. This new drug was more effective and less toxic 
compared to trastuzumab + chemotherapy in clinical trials (Verma 2012; Hurvitz 2010). 
 
Heikki Joensuu’s research team from the molecular oncology in the University of Hel-
sinki (Biomedicum Helsinki) is researching the different mechanisms of cancer. One of 
the ongoing projects there, researched by Ph. D. Mark Barok, is to study how T-DM1 is 
bounded and carried in exosomes secreted by cancer cells, and how T-DM1 bounded 
exosomes affects cells in the tumor microenvironment. 
 
A quick look to the Theseus database revealed that there is not a single thesis, which 
would deal about exosomes. The main objective of this thesis is to provide an insight of 
how such small and challenging nanovesicles can be studied. 
 
 The guiding scientific questions studied during the working process of this thesis were: 
 
• Is there exosomes in the samples collected from cell cultures? 
• Is there HER2 expression in exosomes? 
• Is there T-DM1 on the surface of the exosomes prepared from T-DM1-treated 
cancer cells? 
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The subjects were studied using different methods, such as: cell culturing, preparation 
of exosomes by differential ultracentrifugation, characterization of exosomes by flow 
cytometry.  
 
Mark Barok guided my thesis. Senior Lecture Hannele Pihlaja from Helsinki Metropolia 
University of Applied Sciences provided mentoring and feedback during the different 
phases of the thesis. Elisa Sonne provided peercomments in the last phase of the the-
sis. 
2 Introduction to the topic 
 
2.1 Extracellular vesicles and exosomes 
 
Exosomes are part of the heterogeneous group of extracellular vesicles (EV’s). The 
nomenclature can be quite confusing as the vesicles are referred to by many different 
names, such as: apoptotic bodies, ectosomes, exosomes, nanovesicles, matrix vesi-
cles… The list goes on. In literature exosomes are often describe as particles smaller 
than 100 nm in diameter that are actively secreted from cells, while microvesicles are 
considered larger than 100 nm and often buds of the surface. (Witwer 2013; Lötvall 
2015.) 
 
2.1.1 A brief history 
 
Described for the first time in 1983, these vesicles were pretty much designated just as 
cellular garbage cans acting to discard unwanted molecular components. They re-
mained little studied for the next ten years. (Théry 2011.) The concept of exosomes 
surfaced again in 1996, when a research team showed that Epstein–Barr virus trans-
formed B-lymphocytes secreted exosomes that bore molecules essential for the adap-
tive immune response. Later studies provided the basis for the hypothesis that exo-
somes could play an active role in intercellular communication. (Raposo 1996: 1161-
1172.) 
 
The big breakthrough came several years later in 2007, when the group of Jan Lötvall 
in Sweden provided convincing description, in a paper called “Exosome-mediated 
transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange be-
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tween cells”, of the presence of mRNA and microRNA inside these vesicles. It was 
showed, at least in vitro, that some of that RNA present in the exosomes could be 
translated into proteins in the target cells. Ever since the breakthrough, the interest in 
these nanoparticles has spiked exponentially. (Théry 2011; Valadi 2007: 654- 670) 
 
2.1.2 Composition, biogenesis and function 
 
Exosomes are generated by both eukaryotic and prokaryotic cells (Buzas – György – 
Nagy – Falus − Gay 2014). They have been reported to be present in every biofluid 
and can travel to distant tissues from the original site they were excreted from (Witwer 
2013; Tickner – Urquhart – Stephenson – Richard – O’Byrne 2014: 1). The production 
of nanovesicles is a highly conserved process. It has been showed that nanovesicles 
are present, for example in bacterias, plants, yeast and parasites (Lötvall 2015). 
 
Exosomes contain a specific subset of proteins from endosomes, the plasma mem-
brane and the cytosol. They form inside eukaryotic cells and are released to cell micro-
environment. (Kowa – Tkach − Théry 2014.) They do not contain proteins of nuclear, 
mitochondrial, endoplasmic reticulum or Golgi- apparatus origin. When analyzed by 
whole-mount electron microscopy, exosomes appear as a flattened sphere that is lim-
ited by lipid bi-layer. (Théry – Zitgovel – Amigorena 2002.) 
 
There is no consensus on the exact function of these nanovesicles, but there are some 
hypotheses. First of all, exosomes could bear combinations of ligands that would en-
gage different cell-surface receptors simultaneously. Second, exosomes could bind to 
target-cell membranes, which would bear “new” surface molecule, and potentially ac-
quire new adhesion properties. Third, exosomes could fuse with target cells and ex-
change membrane proteins and cytosol between the two cell types. (Théry − Zitvogel− 
Amigorena 2002) Nonetheless, it is agreed that they play an important role in cell to 
cell communication. 
 
Extracellular vesicles and exosomes have gained a lot of attention in the past ten years 
both as mediators of intercellular communication and potential cancer biomarkers. 
Several reports indicate that cancer cells release more extracellular vesicles than nor-
mal cells and the biomolecular cargo (proteins, lipids and nucleic acid) is reflective to 
the cells origin. Knowledge about the content of extracellular vesicles derived from tu-
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mor cells with differing stages of aggression could be used to establish new diagnostic 
approaches using patient-derived vesicles from body fluids. (Nawaz 2014.) 
 
2.1.3 Role in tumor microenvironment 
 
The tumor microenvironment is considered as comprised of a heterogeneous popula-
tion of cancer cells, stroma cells and tumor-infiltrating immune-cells that all interact with 
each other contributing to tumor development and progression (Lu − Huang − Hanash 
– Onuchic − Jacob 2014). 
 
Recent studies have shown that exosomes can have a bimodal role in cancer. Tumor 
derived exosomes can manipulate the local and systemic environment to aid cancer 
growth, angiogenesis and dissemination. They can also travel to distant sites to pro-
mote the generation of the pre-metastatic niche. Exosomes may also manipulate the 
immune system to elicit an anti–tumor response by recruiting cells to enhance tumor 
invasion, tumor angiogenesis and dissemination. (Kahlert − Kalluri 2013; Tickner 
2014.) 
 
Preliminary results from other studies suggest that exosomes’ mediated transfer of 
proteins between cancer cells can lead to chemoresistance (Kahlert 2013: 433). For 
example, a recent study by Corcoran and al. concluded that exosomes from different 
docetaxel-resistant prostate cancer cell lines may, in part, confer chemoresistance to 
non-resistant prostate cancer cell lines (Corcoran 2012). 
 
2.2 HER2 positive cancers 
 
HER2 is the abbreviation of human epidermal growth factor receptor 2 and is a mem-
ber of the epidermal growth factor receptor (EGFR) family (Bang 2010). The amplifica-
tion or overexpression of HER2 has been shown to play an important role on the de-
velopment of certain types of breast and gastric cancers. It can be used as a biomarker 
and is commonly tested as it dictates how the cancer will be treated. HER2 positive 
cancer can also be diagnosed in gastric, gastroesophageal, ovarian, endometrium, 
bladder, and salivary duct cancers. Trastuzumab is commonly used to treat HER2 posi-
tive breast cancer. It is also used for the treatment of patients with HER2 positive meta-
tasic gastric cancer. (Isola 2014.) 
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2.3 Trastuzumab emtansine, an anti-HER2 antibody-drug conjugate 
 
Antibody-drug conjugates (ADCs) are structurally composed of a monoclonal antibody, 
a small chemical cytotoxic drug and a linker. The ADC is delivered specifically to the 
target cells by the antibody, the cytotoxic drug kills the target cells; the antibody and the 
cytotoxic drug are linked stably by the linker (Erickson 2006: 4426). Trastuzumab em-
tansine (Kadcyla®), shortly T-DM1 is an ADC that consist of trastuzumab as the mono-
clonal antibody and DM1 as the cytotoxic drug. 
 
Trastuzumab (Herceptin®) is a monoclonal antibody that selectively binds with high 
affinity to the extracellular domain of the human epidermal growth factor receptor 2. 
Trastuzumab has many mechanisms of action such as down-regulation of HER2 in the 
plasma membrane, inhibition of HER2 ectodomain shedding and HLA-I-restricted anti-
gen presentation. It also kills cancer cells by inducing apoptosis and inhibiting angio-
genesis. (Barok 2014.) Despite its diverse mechanisms of action, a significant part of 
patients treated with trastuzumab either do not respond initially or relapse after experi-
encing a period of clinical response. (Phillips 2008: 9280.) 
 
Emtansine, or DM1, is a chemotherapy drug that kills cancer cells by causing mitotic 
arrest, disrupting intracellular trafficking and inducing apoptosis. Even though DM1 has 
more pronounced anti-tumor effects, trastuzumab mediated effects should not be un-
derestimated as the continuation of trastuzumab based therapies beyond breast cancer 
progression might be beneficial. (Barok 2014.) T-DM1 has been approved for the 
treatment of metastatic breast cancer in 2013 after proving its efficacy and safety in 
clinical trials (FDA 2013). 
 
Even though primary resistance of HER2 positive metastatic breast cancer to T-DM1 
seems to be relatively infrequent, most patients treated with the drug develop acquired 
drug resistance (Barok – Joensuu − Isola 2014). 
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Figure 1. Trastuzumab emtansine and its internalization into a target cell (Jwatch 2012).  
 
In T-DM1, an average of 3.5 DM1 molecules are bound to one molecule of 
trastuzumab via a non-reducible thioether linker. In this ADC, trastuzumab is responsi-
ble to carry the cytotoxic drug (DM1) to the HER2-positive cancer cells. After binding to 
cell-surface HER2 receptors, T-DM1 is internalized by the target cancer cells which is 
followed by the intracellular degradation of the trastuzumab and linker parts of T-DM1 
resulting of the release of the free DM1 inside the cancer cells (Figure 1.). (Barok 
2014.) 
3 Methods  
 
The size of exosomes (30-100 nm) falls below the optical resolution of conventional 
light microscope, which makes a conventional light microscope useless to image exo-
somes. To prove that exosomes are present in a sample, different approach is needed. 
As mentioned before, in this project exosomes will be studied by cell culture, exosome 
purification and characterization.  
 
Every exosome harvesting protocol used by researches is slightly different from the 
other. The difference between these protocols may lead to the purification of different 
subtypes of exosomes. That is why it is important to always mention what kind of mate-
rials, centrifuges and rotors were used during the purification. (Lötvall 2015.)    
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3.1 Cell culture 
 
Cell culture means growing cells artificially in a tube or in a specific container. Cells 
need a medium that contains essential organic and inorganic compounds, such as:  
glucose, vitamins, amino acids and inorganic ions. The exact cultivation protocol varies 
from cell type to cell type. (Saarela 2013.) 
 
3.1.1 Aseptic technique 
 
Using aseptic techniques is important to avoid infections of the cells when culturing 
them. The cells can only grow properly in an environment free of other microorganisms, 
such as: bacteria, viruses, fungi. Nonsterile supplies, medium, reagents and dirty work 
surfaces as well as air borne particles are the main source of contaminants and micro-
organisms. Incubators are seldom completely sterile, but keeping them clean with regu-
lar decontamination procedures and using sealed, vented cap culture vessels should 
be enough to keep the cells uninfected (Ryan 2008).   
 
Aseptic technique is designed to provide a barrier between microorganisms in the envi-
ronment and the cell culture. The elements in aseptic technique are sterile work area, 
good personal hygiene, sterile reagents and media and sterile handling. 
 
To keep surfaces clean from contaminants, it should always be wiped with 70% ethanol 
before and after use. Everything that is put inside the laminar flow hood has to be also 
cleaned with ethanol. Commercial media and reagents undergo strict quality control to 
ensure their sterility. Pouring liquid directly from flasks or bottles should be avoided to 
keep their sterility. Sterile work should always be done inside a disinfected laminar flow 
hood. 
 
Good personal hygiene means using proper protecting equipment, such as laboratory 
coats and gloves, keeping long hair tied in the back and your hands clean. This reduc-
es the probability of contaminating the working surfaces with skin flakes. It also pro-
tects from any spillages from the cell culture, which is important when working with 
biohazardous materials. (Aseptic technique 2015.) 
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3.1.2 Contaminations in cell cultures 
 
Although cell cultures are very popular among life science researchers, they can be 
very difficult tool to work with in the laboratory. Cell cultures make a dynamic, ongoing 
use of living things and often respond to our mistakes not only by erratic behavior but 
by dying as well. (Ryan 2008.) 
 
Erratic culture behavior can take many forms; unusual growth patterns or inconsistent, 
spotty, and uneven cell attachment are the most common problems. A serious and very 
widespread problem that alters the characteristic growth, metabolism, morphology, 
attachment, and membranes of the cell cultures is mycoplasma. These bacteria-like 
microbes are the smallest self-replicating organisms known (0.3-0.8 µm in diameter), 
they lack a cell wall making them almost invisible to microscopic observation and they 
are fastidious in their growth requirements. Unlike other bacterial infections, they do not 
cloud the growing media or leave any other visible signs of contamination- not even 
when growing in high density. Mycoplasma spreads easily through contaminated sur-
faces and media. (Ryan 2008.) 
 
3.1.3 Used cell lines 
 
In this study we used four types of cell lines: TIME, SNU-216 and SKBR3 and JIMT-1. 
TIME and SKBR3 cell lines are from American Type Culture Collection (abbreviated 
ATCC), SNU-216 is from Korean Cell Line Bank and JIMT-1 from German Collection of 
Microorganisms and Cell Culture.  
 
TIME cells are human endothelial cells originally derived from the foreskin of a neona-
tal. TIME cells have been immortalized by using a retrovirus, thus making the cells bio-
hazardous. (ATCC 2014.) However, it has been showed previously in this study that 
the virus is not present in this cell line, and it should be safe to handle the culture under 
normal, sterile conditions. 
 
SNU-216 is a human gastric cancer cell line established from a nodal metastasis of 
stomach cancer, has moderate amounts of HER2 receptors and is trastuzumab-
resistant. (KCLB 2014.)  
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SKBR3 is a human breast cancer cell line derived from the primary tumor of a breast 
cancer patient and is HER2-positive and trastuzumab-sensitive. It is much more sensi-
tive to T-DM1 than trastuzumab. (ATCC 2014; Barok – Tanner – Köninki – Isola 2011)  
 
JIMT-1 is also a human breast cancer cell line which has been established from the 
pleural effusion of patient with grade 3 invasive ductal breast cancer. It is described to 
carry HER2 oncogene amplification and to be insensitive to trastuzumab, however, it is 
sensitive to T-DM1. (DSMZ 2015; Barok 2011.) 
 
 
Figures are the light microscopy images of the cell lines in different states of conflu-
ence. Figures 2-4 are self taken, and figure 4 is from ATCC official webpage. 
 
3.1.4 Protocol 
 
Despite of the difference between the cell lines, the cells were cultured using the same 
washing and centrifuge protocols. Only the culture medium differed from cell line to cell 
line. The materials are described in detail in the following table. 
 
 
 
 
 
 
 
 
 
Figure 2. JIMT-1 Figure 3. SKBR3 Figure 5. TIME (picture 
from ATCC) 
Figure 4. SNU-216 
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Table 1. Material list in detail. 
Materials Other information Company 
Media: 
DMEM 
RPMI 1640   
Vascular cell basal  
 
Supplements: 
Blasticidin 
Penicillin-Streptomycin – Glu-
tamine 
 
Others: 
Phosphate buffered saline 
(PBS) 
Trypsin- EDTA  
Trypsin 10x 
Fetal bovine serum (FBS) 
 
Conical tubes (Falcon) 
Cell culture vessels 
Multi layered culture vessel 
 
Incubator 
 
Waterbath 
Cell culture hood 
Pipets  
Centrifuge 
 
High glucose, without 
glutamine 
Low glutamine 
 
 
 
 
 
 
 
 
 
 
 
 
 
50 ml 
160 ml, 75 ml 
10 layered  
 
Autoflow IR direct heat 
CO2 incubator 
SW23 
Clean Wizard W130 
 
IEC Centra CL2 
 
Lonza 
Gibco by Life Technologies 
ATCC  
 
 
Invitrogen  Life Technologies 
Gibco  Life Technologies 
 
 
 
Lonza 
 
Lonza 
Lonza 
Gibco Life sciences 
 
Corning  
NUNC 
Corning 
 
Nuaire 
 
Julabo 
Kojair 
Biohit 
Thermo Electron Corporation 
 
 
Table 2. Used supplements in commercial media 
Cell line Used commercial medium: Supplemented with: 
TIME Vascular cell basal medium Blasticidin 
SNU-216 RPMI 10% FBS, 1% PS-Glut 
SKBR3 DMEM 10%FBS, 1% PS-Glut 
JIMT-1 DMEM 10%FBS, 1% PS-Glut 
 
First the wanted the cells to be separated from the mother culture. The mother culture 
medium is first discarded and the cells are washed with phosphate buffered saline 
(PBS) as it will be referred as later on. Detaching the cells from the bottles growing 
surface happens by adding of trypsin to the culture. The cultures are incubated for 10-
15 minutes at 37 °C. 
 
After making sure the cells are completely detached from the growing surface by using 
a light microscope, the activity of trypsin-EDTA is inhibited with culture medium. The 
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volume of used culture medium should be twice the amount of trypsin. The cells are 
then collected to a Falcon tube and centrifuged with 1000 rpm for 7 minutes.  
 
The supernatant is thrown away and the pellet is suspended in some culture medium. 
The cell-suspension is added to a new culture bottle and cultured in an atmosphere of 
5% CO2 and 37 °C. Every 2- 3 days the cells have to be subcultivated. 
 
 
Figure 6.   Cell culturing in a hood 
 
 
3.1.5 Testing mycoplasma from the cell lines 
 
One of the cell lines were having troubles to grow properly while the others had prob-
lems in attachment. This lead to the thought, that there might be something contami-
nating the cells. After a bit of research I decided to test them with Venor GeM by Mi-
nerva Biolabs, a mycoplasma detection kit for PCR.  
Figure 7. Mycoplasma PCR testing kit results after electrophoresis. 
1.JIMT-1 
2. SNU-216 
4. Vascular cell basal 
5.DMEM 
6. POS. CONTROL 
7.NEG. CONTROL 
3. SKBR3 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
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The results were negative. As it can be seen from the figure, the 30 minute run was not 
enough to clearly confirm the results. After 30 more minutes the bands on the agar gel 
became separated clearly enough to read the results. The reason why DMEM did not 
give a band is probably because of the serum presented in the sample, which inhibits 
the sample. 
 
After an extensive talk with the members of the research group, it was decided to throw 
away the cell cultures, disinfect the working areas that were in contact with the cell 
lines and restart the cultures again anyway. Although time consuming and expensive, it 
is better to be sure the cells are not infected with mycoplasma, as it might interfere with 
the exosomes. 
 
3.1.6 Standardizing Hyperflask bottles (Corning) 
 
Preparing enough cells for drug treatments requires a lot of culture flasks. Initially we 
had to use ten 160 ml Nunc culture flasks by Thermo Fisher to split them later on into 
30 160 ml Nunc flasks. The limited space of the incubator in use provided a challenge: 
the large amounts of giant sized flasks required almost all space in the incubator, mak-
ing it impossible to culture other cell lines simultaneously. 
 
We found a temporary solution to this problem by trying the 10 layered Hyperflask by 
Corning. This flask took the space of one 160 ml Nunc flask and allowed us to incubate 
several cell lines at the same time.  
 
I was able to standardize a handling protocol for the Hyperflask. During this work we 
were able to grow successfully JIMT-1 and SKBR3 cells. 
 
 
 
 
 
 
 
 
Figure 8. Comparison of cell culture flask sizes. Far right is the Hyperflask. 
1. 
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3.1.7 Treating the cell with T-DM1/trastuzumab for exosome preparations 
 
One of the most important works during this thesis was harvesting exosomes from 
trastuzumab/ T-DM1/ PBS treated cells. The exosomes will be used later on in this 
study. 
 
The confluence of the cell culture has to be ~70% before they can be treated with the 
drugs. Cells are washed with PBS for 3 times to make sure the growing medium is 
gone. Then the cells are incubated for 5 minutes in ice cold PBS. This is to stop the 
cells from internalizing the drugs right away. The cells are treated with trastuzumab or 
T-DM1 and incubated for 20 minutes.  
 
The cells are once again washed three times with PBS and incubated in ice cold PBS 
for 5 min. Since we planned to harvest exosomes from the treated cell cultures, we 
added exosome depleted medium to make sure the vesicles harvested from the medi-
um were originated from the cells. The cells are incubated for 24 hours. 
 
3.1.8 Collecting exosomes 
 
When collecting exosomes from cell cultures, you have to keep in mind that we are 
collecting extremely tiny particles (<100 nm). Cells secrete exosomes to their surround-
ings and can be harvest directly from the culturing media. 
 
To make sure the collected nanovesicles are solely from the cells, it is important to 
culture cells in an exosome depleted media. FBS is often used to supplement culturing 
media as a nutrient to the cells. Despite of being filtered, commercially available FBS 
contains a lot of EV’s that would interfere with the exosomes harvested for experi-
ments. (Shelke – Lässer – Gho – Lötvall 2014.) There is commercially available exo-
some free FBS, but it is possible to prepare it in the laboratory as well. First a 20% 
FBS, 1% PS-Glut medium is prepared. The media is then ultracentrifuged overnight in 
100 000 x g and 4°C for 18h. After centrifugation, the media is collected. Avoiding the 
formed pellet in the tubes, the exosome depleted medium is collected to a container. 
Then, through a 0,4 um sterile filter, the media can be aliquot for later use.  
In purposes of exosome harvest, the cells were incubated in exosome depleted medi-
um at least for 3 days. 
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3.2 Purification 
 
Exosomes are harvested from cultured medium of cancer cells. The best way to obtain 
large amount of exosomes is by using a series of centrifugation and ultracentrigation. 
Ultrafiltration is also used to purify large amounts of exosomes. Exosomes can also be 
purified by trapping them on beads bearing an antibody specific for exosomal surface 
molecules. This easy to use method is and can be used to characterize exosomes 
roughly, but it is not suited for purification of large amounts of exosomes. In this project 
exosomes will be acquired by ultracentrifugation. (Théry 2006.) 
 
3.2.1 Used protocol 
 
The centrifugation protocol used in this study is modified version from the one de-
scribed in the publication “Isolation and characterization of exosomes from cell culture 
supernatants and biological fluid, 2006” by Théry and al. We modified mainly the cen-
trifugation times mentioned in the article.  
 
 
Figure 9. Flow chart of centrifugation. All centrifugation are done at 4°C 
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The flow chart provides the protocols used to purify the exosomes from the harvested 
media. In steps 1-3 the supernatant is centrifuged and the pellet discarded. In steps 4-5 
the pellet is kept and suspended in a large volume of PBS. The purified pellet is sus-
pended in 400 µl of PBS and thawed into Eppendorf Lo-Bind tubes. The samples are 
stored in -80 °C. 
 
Table 3. Centrifuges and models used in exosome purification 
Centrifuge steps Centrifuge model Company Rotor type Bottle type 
1-2 Varifuge 3.0R Heraeus Sepatech 8080 C Conical tubes 50 ml (Falcon) 3 7780 Kubota AG-6512C 
4-5 
XL 90 Ultracentri-
fuge / Optima XL- 
80 Ultracentrifuge 
Beckman Coulter 50.2 Ti 
Polycarbonate 
tubes 26.3 ml 
(Beckman 
Coulter) 
 
Appendix 3 provides the ultracentrifuge protocol after the three first centrifugation 
steps. 
 
3.2.2 Can 2 ultracentrifuges remove unbound T-DM1?  
 
Protein quantitation assay provides information on how the T-DM1 behaves during ul-
tracentrifugation. During this thesis we used Easy- TiterTM Human IgG (H+L) Assay Kit 
by Thermo Scientific. This kit was used in a couple of experiments to measure the IgG 
concentrations of samples. The kit contains monodispersed polystyrene beads coated 
with anti-IgG antibodies. When the beads are mixed with a sample containing IgG, they 
aggregate and cause decreased absorption of light. This means that low IgG concen-
trations yield high absorbance values and high IgG concentrations yield low absorb-
ance values. (Easy-Titer IgG Assay Kits 2015.) 
 
The objective of this experiment was to confirm that two ultracentrifugation steps are 
enough to remove the unbound T-DM1 from the samples. 
 T-DM1 was added from the store stock into PBS to a final concentration of 50 µg/ml, 
10 µg/ ml and 1 µg/ ml. The tubes went through the same two ultracentrifugation steps 
that were done when extracting exosomes from harvested media. A small 100 µl sam-
ple was taken before ultracentrifugation and after ultracentrifugation. The exact proto-
col for this experiment can be seen in Appendix 4.  
 
16 
  
The T-DM1 concentration was measured with Easy-TiterTM kit according to the manu-
factures’ instructions. The absorbance at 405 nm was measured by using Multiskan EX 
by Thermo Electron Corporation. 
 
3.3 Characterization 
 
Identification and characterization of exosomes requires morphological analysis. Char-
acterization involves different methods that reveal different properties of exosomes. 
(Thèry 2006.) In this project, the characterization will be done using flow cytometry.  
 
Flow cytometry is a technology that simultaneously measures and analyzes multiple 
physical characteristics of single particles, usually cells. The properties measured are 
the particles relative size, granularity or internal complexity and fluorescence intensity. 
The characteristics are measured using an optical-to-electronic coupling system that 
records how the cell or particle scatters incident laser lights and emits fluorescence. 
(Introduction to Flow Cytometry 2000.) In the following explained experiments we used 
Accuri C6 Flow Cytometer. 
 
3.3.1  Measurement of the HER2 level of cells 
 
This experiment was done to test T-DM1 binding to cells. SKBR3, SNU-216 and TIME 
cells were collected and sorted into test tubes. JIMT-1 cells were left from this test, as 
M. Barok had done this experiment to this cell line in his previous studies (Barok 2011). 
The labeling was done with two antibodies. T-DM1 was used as the primary antibody 
and binds only to HER2 receptors. Alexa-488-GAHIG (Goat Anti-human IgG) was used 
as the secondary antibody. Alexa 488 is a fluorescent dye conjugated to GAHIG. Since 
the trastuzumab part of T-DM1 is a human IgG, GAHIG binds to T-DM1. 
 
T-DM1 binds with high affinity to the HER2 receptors of the cancer cells. To decrease 
the internalization of T-DM1 by the cells, the labeling has to be done on ice. The exact 
used protocol can be seen in Appendix 1. 
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3.3.2 Measuring T-DM1 from SNU-216 exosomes 
 
In this experiment exosomes were collected from the SNU-216- cell cultures that were 
treated with 1 µg/ml of trastuzumab or T-DM1. The culture medium was changed to 
exosome-depleted medium, then drugs were added to the cells followed by a 24 h in-
cubation of the cells at 37 ºC and 5 % CO2.   
 
Exosomes are too small to be reliably analyzed by direct cell sorting. To overcome this 
problem, exosomes are bound to latex beads of a size that is in the detection range of 
a flow cytometer. After a series of washing and centrifuging the samples were labeled 
with primary antibodies: T-DM1, Alexa-647-anti-CD63 and Alexa-647-isotype control. 
Alexa-647 is the fluorescent dye conjugated to the antibody against CD63. Alexa-488-
GAHIG was used as the secondary antibody, which should bind into T-DM1. To detect 
the fluorescent intensities we used FL-1 and FL-4 channels on the flow cytometer. Fl-1 
was used for detecting the fluorescent intensity of Alexa-488 and FL-4 used for detect-
ing the fluorescent intensity of Alexa-647.  
 
Table 4. Used primary antibodies and their description 
Primary Antibody Produced in Properties 
 
A647-anti-CD63 
(BD	  Pharmigen,	  material	  number:	  
561983)	  
 
Mouse Targets to CD63. Exosome marker. 
A647-isotype control 
(BD	  Pharmigen,	  material	  number:	  
557783) 
 
Mouse 
Negative control. Designed to 
measure non-specific back-
ground signal caused by the 
primary antibody. No specificity 
for target protein (Bioss Anti-
bodies 2015). 
T-DM1 
 
Trastuzumab part (T) is a 
humanized IgG Used to label HER2- sites. 
 
Table 5. Used secondary antibody and its description 
Secondary Antibody Produced in Properties 
 
A488-GAHIG 
(Jackson	  Immunoresearch,	  109-­‐
606-­‐088)	  
 
Goat Binds to human IgG 
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3.3.3 Measuring T-DM1 from SKBR3 exosomes 
 
This experiment was very similar to the one made with SNU-216 cells. The exosome 
preparation from the SKBR3 cells, the labeling protocol and the guiding questions were 
the same as the experiment done with the SNU-216 cells. The cells were treated with 1 
µg/ml of trastuzumab or T-DM1. The treatment protocol can be seen in Appendix 2. 
 
Due to the preliminary results of this experiment, the test was done twice. The second 
time we used three other exosome markers and another secondary antibody, Alexa-
488-GAMIG, as well. The labeling protocol and the flow cytometry channels were the 
same as in the first round. 
 
Table 6. Additional primary antibodies used in this experiment. 
Primary Antibody Produced in Properties 
FITC-anti-CD81 
(Sigma-­‐Aldrich,	  SAB4700233) Mouse 
Reacts with CD81, a member of 
tetraspanin family, expressed in 
the majority of cells (Sigma-
Aldrich 2015). Can be used as 
an exosome marker. FITC is the 
fluorescent dye, detectable in 
FL-1. 
 
Anti-CD9 
(Sigma-­‐Aldrich,	  SAB4700092)	  
 
Mouse Targets to CD9. Exosome mark-er. 
Anti-TSG101 
(Sigma-­‐Aldrich,	  SAB2702167) Mouse 
Binds into ubiquitinated cargo 
proteins. Is required for the sort-
ing of endocytic ubiquitinated 
cargos into multivesicular bodies 
(MVBs). (Abcam 2015.) Can be 
used as an exosome marker. 
 
 
Table 7. Secondary antibodies and their properties 
Secondary Antibody Produced in Properties 
A488-GAHIG 
(Jackson	  Immunoresearch,	  109-­‐
606-­‐088) 
Goat Binds to human IgG 
A488-GAMIG 
(Jackson	  Immunoresearch,	  115-­‐
546-­‐062) 
Goat Binds to mouse IgG 
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3.4  Electron microscope 
 
Electron microscopes use a beam of charged particles instead of light and use elec-
tromagnetic or electrostatic lenses to focus the particles. The resolution is quite aston-
ishing comparing to light microscopies as they can see features as small as tenth of a 
nanometer. This kind of resolution is enough to visualize exosomes with great detail. 
There are different kinds of electron microscopes, each using a different method to 
visualize samples. (FEI Company 2010:4.)  
 
Exosomes can be visualized by using the electron microscope; samples were negative 
stained or immunolabeled with exosome marker anti-CD63, and then with secondary 
antibodies anti-mouse IgG and anti-human IgG. Anti-mouse IgG was used against anti-
CD63 antibody, since anti-CD63 was produce in a mouse. Anti-human IgG is against 
the trastuzumab or T-DM1, since these are human IgGs. The secondary antibodies 
were gold-conjugated.  
 
Negative staining was done to investigate the size and morphology of the vesicles 
while immunostaining was done to examine whether the vesicles have exosome mark-
ers and whether trastuzumab and T-DM1 is bound to exosomes. 
 
The exosomes were pictured using a transmission electron microscopy Jeol JEM-1400 
(Jeol Ltd., Tokyo, Japan). This EM’s magnification range goes from x50 to x800000. 
EM-work was carried out with the assistance of Ph.D. Maija Puhka and with the help of 
the EM-Unit resources (Electron Microscopy Unit, Institute of Biotechnology, University 
of Helsinki). 
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4 Results 
 
4.1 Flow cytometry results of HER2 levels on the cells 
  
The results of this flow cytometry test were analyzed by using the Accuri sofware. The 
histograms are one of the many formats in which flow cytometry results can be pre-
sented. The horizontal axis represents the fluorescence intensity (FI) detected in the 
appropriate channel (FI of FITC and Alexa-488 was detected in FL-1, FI of Alexa-647 
was detected in FL-4) and the vertical axis represents the detected events.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The high fluorescent levels of T-DM1- A488 GAHIG confirmed that T-DM1 does bind 
with high affinity to the SKBR3 cells, meaning there are HER2 receptors on the cells. In 
the histogram the mean fluorescent intensity of Alexa488-GAHIG is a bit higher than 
the background’s fluorescent level (see the table above). This means there is some 
binding of Alexa488- GAHIG to the cells that were not labeled with T-DM1 before. This 
is the unspecific binding to the cells and provides a background to the T-DM1 – 
Alexa488-GAHIG labeled cells. The green T-DM1– Alexa488-GAHIG is detected fur-
ther in the horizontal axis, meaning there is T-DM1 binding.  
  
Figure 10. SKBR3 data. 
SKBR-­‐3 Mean	  FL1-­‐A	  
Background 5	  827,35
A488	  GAHIG 6	  102,65
TDM1-­‐	  A488	  GAHIG 1	  103	  887,59
SKBR3 Mean fluorescent intensity 
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The mean fluorescent of T-DM1 – Alexa488-GAHIG labeled SNU-216 cells is lower 
than that of SKBR3 cells (212 802, 1 103 887, respectively). This indicates that SNU-
216 cells have lower HER2 levels than SKBR3 cells. Again, the histogram is similar to 
the one of the SKBR3-cells. 
 
 
  
SNU-216: Mean fluorescent intensity 
 
Figure 11.   SNU-216 data. 
SNU-­‐216 Mean	  FL1-­‐A	  
	  Background	   4	  276,22
	  A488	  GAHIG	   6	  573,64
	  TDM1-­‐	  A488	  GAHIG 212	  802,97
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Surprisingly the TIME cells also bind some T-DM1. As seen from the table above, the 
mean FL1-A of T-DM1- A488- GAHIG is higher than that of A488- GAHIG (17 809.55, 
33 384. 14, respectively). 
 
This can be explained by the nature of the TIME cells. TIME cells were established 
from the foreskin epithelia cells of a neonatal. It is described in literature that neonatal 
cells express Fc receptors, also known as the Brambell receptor. Its function is evident 
in early life in the transport of IgG from the mother to fetus and neonate for passive 
immunity (Kou 2010: 777).  Since T-DM1 is essentially an IgG with a drug attached to 
it, it is possible that it binds to the Fc receptors as well. Other possible explanation is 
that TIME cells do express HER2 receptor after all, even though insignificantly compar-
ing to the other cell lines (33 384.14, 1 103 887.59 respectively from the SKBR3 data 
table). 
 
 
 
  
Figure 12.  TIME data. 
 TIME detected fluorescent levels 
TIME Mean	  FL1-­‐A	  
Background 3	  542,34
A488	  GAHIG 17	  809,55
TDM1-­‐	  A488	  GAHIG 33	  384,14
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The conclusive table shows all the histograms and mean fluorescent intensities from 
this experiment. As it was concluded earlier, the SKBR3 cells bind the most T-DM1 and 
thus have the highest HER2 receptor level. The SNU-216 cells also have HER2 recep-
tors, although the HER2 receptor expression is less compared to SKBR3 cells (see the 
table above). In comparison TIME cells do binds T-DM1 only a little. The histogram 
concludes the same thing: the shift in horizontal FL1-A axis means shows that HER2 of 
SKBR3 is higher than SNU-216 and TIME. The further the histogram stands in the axis, 
the more the measured sample has HER2. 
 
  
All	  Samples Mean	  FL1-­‐A	  
SKBR3	  TDM1-­‐	  A488	  GAHIG 1	  146	  828,96
SNU216	  TDM1-­‐	  A488	  GAHIG 198	  956,36
TIME	  TDM1-­‐	  A488	  GAHIG 31	  763,37
Figure 13.  Conclusive data. 
 Mean TDM1- A488 GAHIG fluorescence of all the cells 
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4.2 FC results of T-DM1 from SNU-216 exosomes  
 
In the following chapters the results of this experiment will be discussed by using charts 
and tables containing the numeric values of the immunolabeled exosomes.  
 
The results of this flow cytometry test were analyzed by using the Accuri software. 
Charts were made using Excel. 
 
4.2.1 Exosomes harvested from PBS treated SNU-216 cell 
 
 
 
 
Table 8. Exosomes harvested from PBS-treated SNU-216, numeric values 
 
 
 
 
 
 
 
 
 
T-DM1 binds only to the HER2-receptors. Alexa488-GAHIG binds to T-DM1. Thus, the 
exosomes treated only with Alexa 488-GAHIG, would provide a background on how the 
secondary antibody behaves, while the exosomes labeled with both T-DM1 and 
Alexa488-GAHIG reveals the HER2-levels of the exosomes.  
 
	   	  
Mean	  FL1-­‐A	  	   Mean	  FL4-­‐A	  	  
Exosomes	  
prepared	  from	  
PBS-­‐treated	  
SNU-­‐216	  cells	  
Bg	   257,01	   196,03	  
A647isotype	  control	  	   256,48	   195,16	  
A488-­‐GAHIG	   368,92	   195,69	  
A647-­‐aCD63	   256,93	   280,03	  
A647-­‐aCD63_A488-­‐GAHIG	   294,71	   254,78	  
TDM1_A488-­‐GAHIG	   3	  308,50	   194,01	  
A647-­‐aCD63_TDM1_A488-­‐GAHIG	   2	  304,14	   249,4	  
Figure 14. T-DM1 levels. Figure 15. Exosome marker. 
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The same goes with the Alexa 647 isotype control: as mentioned earlier the A647 iso-
type control is designed to measure non-specific background signal caused by the pri-
mary antibody and has no specificity for target protein. It sets the background from 
which the exosome marker anti CD63 can be compared to 
 
In figure 14 low fluorescent levels of A488-GAHIG indicate that there is no T-DM1 in 
the sample. It is only natural, as exosomes that were derived from the PBS treated 
cells should not have T-DM1 at all on their surface. High fluorescent levels of T-DM1 − 
A488-GAHIG means there are HER2- receptors on the exosomes. In figure 14 we can 
see that there is some CD63 binding in the samples, indicating that the vesicles in the 
sample are probably exosomes. The difference between Alexa647-isotype control and 
Alexa647 – antiCD63 is not very high though.  
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4.2.2  Exosomes harvested from trastuzumab treated SNU-216 cells 
 
 
 
Table 9. Exosomes harvested from trastuzumab-treated SNU-216 cells, numeric values 
 
 
 
 
 
 
 
 
 
In figure 16 we can see that the level of Alexa488-GAHIG in this sample is higher than 
the one on the PBS treated. This supports the hypothesis that there is trastuzumab on 
the surface of the exosomes. After labeling the exosomes with both T-DM1 and Alexa 
488-GAHIG, the fluorescent levels rise. This indicates that there are unsaturated, free 
binding sites for HER2 receptors on the surface of the exosomes. 
 
 
  
	  	   	  	   Mean	  FL1-­‐A	  	   Mean	  FL4-­‐A	  	  
Exosomes	  
prepared	  
from	  
trastuzumab-­‐
treated	  SNU-­‐
216	  cells	  
Bg	   251,68	   179,09	  
A647isotype	  control	  	   252,14	   174,42	  
A488-­‐GAHIG	   849,22	   178,52	  
A647-­‐aCD63	   252,82	   507,3	  
A647-­‐aCD63_A488-­‐GAHIG	   1083,54	   495,43	  
TDM1_A488-­‐GAHIG	   2458,04	   177,97	  
A647-­‐aCD63_TDM1_A488-­‐GAHIG	   2223,62	   512,63	  
Figure 16. T-DM1 levels. Figure 17. Exosome marker. 
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4.2.3  Exosomes harvested from T-DM1 treated SNU-216 cells 
 
 
 
 
Table 10. Exosomes harvested from T-DM1- treated SNU-216 cells, numeric values 
 
 
 
 
 
 
 
 
The vesicles were positive for an exosome marker (CD63), in order to get a confirma-
tion that the measured particles are truly exosomes, the samples must be tested further 
with different exosome markers or by visualizing them with electron microscopy.  
 
 
  
	  
	  	   Mean	  FL1-­‐A	  	   Mean	  FL4-­‐A	  	  
Exosomes	  
prepared	  from	  
TDM1-­‐treated	  
SNU-­‐216	  cells	  
Bg	   261,22	   174,32	  
A647isotype	  control	  	   257,2	   174,86	  
A488-­‐GAHIG	   525,07	   174,08	  
A647-­‐aCD63	   248,81	   559,56	  
A647-­‐aCD63_A488-­‐GAHIG	   496,16	   599,75	  
TDM1_A488-­‐GAHIG	   2943,29	   176,21	  
A647-­‐aCD63_TDM1_A488-­‐GAHIG	   2	  780,22	   487,65	  
Figure 18. T-DM1 levels. Figure 19. Exosome marker. 
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4.2.4 Conclusive data on SNU-216 exosomes 
 
 
 
 
 
 
 
In figure 20 we can see the comparison between A488- GAHIG labeling and T-DM1- 
A488-GAHIG labeling. Exosomes harvested from the trastuzumab and T-DM1 treated 
cell labeled with A488 GAHIG have a higher fluorescent level than in case exosomes 
from PBS-treated cells: this indicates that these exosomes have trastuzumab and T-
DM1 on their surface (368 – 849 – 525 from the tables 8-10). Interestingly the amount 
of saturated HER2-receptors is initially higher in the trastuzumab treated cells, while 
the PBS and T-DM1 treated have very similar amounts (compare the blue bars). In the 
case of all the three treatments we can see also a high amount of free unsaturated 
HER2 receptors that can bind significant amounts of T-DM1, which can be seen as the 
difference between the red and blue bars.  
 
Figure 20. T-DM1 levels, conclusive chart. 
Figure 21. Exosome markers, conclusive chart. 
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Figure 21 provides a comparison between the detected exosome marker CD63 in the 
samples. This might indicate that the trastuzumab and T-DM1 treatment can increase 
the CD63 level of the exosomes. 
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4.3 FC results of exosomes harvested from PBS/trastuzumab/T-DM1-treated SKBR3 
cells 
 
Surprisingly the results in this test were for the part of the exosomes very different to 
the results of SNU-216 cells. We did not get any significant increase in FL-4 channels 
when measuring A647-aCD63 sample, as the SNU-216 cells established.  
In other words, the particles we measured might not be exosomes. To test this we la-
beled the samples with other known exosome markers. 
 
On the other hand, we did get a high increase in TDM1-A488GAHIG, which means 
there is clear T-DM1 binding.  
 
4.3.1 Results from the first testing 
 
 
 
 
 
 
Figure 22. T-DM1 levels, conclusive chart
Figure 23. Exosome marker, conclusive data 
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Figures 22-23 shows the results from the exosomes only labeled with the same primary 
and secondary antibodies as the SNU-216 exosomes in a conclusive chart. 
 
In figure 22 we can see that the T-DM1 binding follows pretty much the same pattern 
established by the SNU-216 cells. The blue bar shows Alexa488-GAHIG binding while 
the red shows the T-DM1 – Alexa488-GAHIG. The comparison between the two of 
them shows the amount of free T-DM1 binding sites in the exosomes. 
 
As it can be seen in figure 23, the exosome marker CD63 does not react the same way 
as with the exosomes from SNU-216 cells. Both green and orange bars stay in the 
same level. 
 
Table 11. Exosomes harvested from PBS treated SKBR3 cells, numeric values 
 
 
Table 12. Exosomes harvested from trastuzumab treated SKBR3 cells, numeric values 
 
 
Table 13. Exosomes harvested from T-DM1 treated SKBR3 cells, numeric values 
  
 
Mean	  FL1-­‐A	   Mean	  FL4-­‐A	  
Bg 262,82 175,6
A647isotype	  control	   409,17 176,29
A488-­‐GAHIG 1300,19 180,03
A647-­‐aCD63 376,81 182,83
A647-­‐aCD63_A488-­‐GAHIG 322,87 177,72
TDM1_A488-­‐GAHIG 13784,73 176,8
A647-­‐aCD63_TDM1_A488-­‐GAHIG 179,27
Exosomes	  
prepared	  
from	  PBS	  
treated	  
sKBR3	  cells
Mean	  FL1-­‐A	  Mean	  FL4-­‐A	  
Bg 252,43 176,09
A647isotype	  control	   289,05 175,88
A488-­‐GAHIG 709,38 176,25
A647-­‐aCD63 277,03 181,63
A647-­‐aCD63_A488-­‐GAHIG 620,44 176,98
TDM1_A488-­‐GAHIG 14	  673,95 176,72
A647-­‐aCD63_TDM1_A488-­‐GAHIG 11	  273,29 176,72
Exosomes	  
prepared	  
from	  
trastuzum
ab	  treated	  
SKBR3	  
cells
Mean	  FL1-­‐A	  Mean	  FL4-­‐A	  
Bg 269,87 175,8
A647isotype	  control	   325,25 178,09
A488-­‐GAHIG 489,76 178,51
A647-­‐aCD63 294,38 178,41
A647-­‐aCD63_A488-­‐GAHIG 533,82 175,24
TDM1_A488-­‐GAHIG 12	  140,82 176,51
A647-­‐aCD63_TDM1_A488-­‐GAHIG 9	  293,41 178,31
Exosomes	  
prepared	  
from	  
TDM1	  
treated	  
SKBR3	  
cells
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4.3.2 Exosomes harvested from PBS-treated SKBR3 cells 
 
 
 
 
 
 
 
 
 
In figure 24 we can see, what the SNU-216 cells already stated: the exosomes from the 
PBS treated cells did not have T-DM1 on their surface. In figure 25 we can see the 
different exosome markers used in this test. The samples were positive for TSG101 
exosome marker as well as they showed some CD9 positivity. Fluorescent levels of 
both FITC and Alexa-488 were detected in the FL-1 channel of the flow cytometer.  
 
Table 14. Exosomes harvested from PBS treated SKBR3 numeric values 
 
 
 
 
  
Figure 24. T-DM1 levels Figure  25. Exosome markers 
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4.3.3 Exosomes harvested from trastuzumab treated SKBR3 cells 
 
 
 
The exosomes harvested from the trastuzumab treated cells followed the same pattern 
as the exosomes harvested from the PBS treated cells. These exosomes showed slight 
CD9 positivity and a very high TSG101 positivity. 
 
Table 15. Exosomes harvested form trastuzumab treated SKBR3 cells, numeric values 
 
 
 
  
Figure 26. T-DM1 levels Figure 27. Exosome markers 
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4.3.4 Exosomes harvested from T-DM1 treated SKBR3 
 
 
The exosomes harvested from the T-DM1 treated cells followed the same pattern set 
by the PBS/trastuzumab treated cells. 
 
Table 16. Exosomes harvested from T-DM1 treated SKBR3, numeric values 
 
 
In the case of T-DM1 treated cells, the exosomes also seem to express CD9 marker 
better than the other treated cells. The TSG101 positivity was very clear in these exo-
somes as well.  
 
 
  
Figure 28. T-DM1 levels Figure 29. Exosome markers 
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4.3.5 Conclusive data on SKBR3 exosomes 
 
Figure 30. T-DM1 levels, conclusive chart 
 
 
Figure 31. TSG101 levels, conclusive chart 
 
The figures 30-31 conclude the information above and make a comparison between 
the differently treated cells. As seen in figure 30 the exosomes harvested from the 
trastuzumab treated SKBR3 cells seem to have the most saturated HER2 receptors 
(see the blue bars from figure 30). 
 
Figure 31 shows the levels of the exosome marker TSG101 in comparison of the high-
est Alexa488-GAMIG.  
 
  
36 
  
4.4 Results of T-DM1 quantitation assay 
 
The results gave expected results. As it was anticipated, the ultracentrifugation protocol 
is enough to remove T-DM1 from the sample bellow measurable quantities. 
 
 
Figure 32. Standard curve for T-DM1.   
 
The standard curve was generated by using the data on table 6. 
 
Table 17. T-DM1 standard curve values 
	  
Mean	  absorbance	   Concentration	  (ng/ml)	  
Ln	  (concentra-­‐
tion)	  
A	   0,715	   500	   6,214608098	  
B	   0,871	   250	   5,521460918	  
C	   1,025333333	   125	   4,828313737	  
D	   1,093666667	   62,5	   4,135166557	  
E	   1,195	   31,2	   3,440418095	  
F	   1,215	   15,6	   2,747270914	  
G	   1,275666667	   0	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The tables above show the results of this test. This test was done on three separate 
days. The orange color on the tables shows the concentration of the first samples be-
fore the first ultracentrifugation. The green is for the T-DM1 concentration of the sam-
ples after the second ultracentrifugation. The detection limits of the used kit ranges 
from 15,6 ng/ml to 500 ng/ml, as shown in table 17. The labeling of the samples in ta-
bles 18-20 means D(day)/sample number. For further information on the samples, refer 
to appendix 5. 
 
In conclusion the results were every time the same, no matter what the starting con-
centration was. Samples 1 and 6 showed that there is present T-DM1, after two ultra-
centrifugations the amount of the T-DM1 in samples 5 and 10 was below the measura-
ble range of the kit. 
 
 
 
Mean Concentration	  (ng/ml)
D1/1 1,200666667 717,6
D1/2 0,566333333 >	  500	  ng/ml
D1/3 1,237666667 <	  15,6	  ng/ml
D1/4 1,240333333 <	  15,6	  ng/ml
D1/5 1,256666667 <	  15,6	  ng/ml
D1/6 1,138333333 204,5593985
D1/7 1,108 52,734375
D1/8 1,294 <	  15,6	  ng/ml
D1/9 1,272666667 <	  15,6	  ng/ml
D1/10 1,297333333 <	  15,6	  ng/ml
Mean Concentration	  (ng/ml)
D2/1 1,066 5807,622505
D2/2 0,623 >500	  ng/ml
D2/3 1,189 33,3112782
D2/4 1,173666667 38,70676692
D2/5 1,219666667 <	  15,6	  ng/ml
D2/6 1,240333333 <	  15,6	  ng/ml
D2/7 0,945333333 195,8874459
D2/8 1,242666667 <15,6	  ng/ml
D2/9 1,255333333 <	  15,6	  ng/ml
D2/10 1,258 <	  15,6	  ng/ml
Table 18. Day 1 results Table 19. Day 2 results 
Mean Concentration	  (ng/ml)
D3/1 0,565666667 >	  500	  ng/ml
D3/2 0,777 400,6410256
D3/3 1,305 <15,6	  ng/ml
D3/4 1,324333333 <	  15,6	  ng/ml
D3/5 1,271333333 <15,6	  ng/ml
D3/6 0,612666667 >	  500	  ng/ml
D3/7 0,668333333 <	  500	  ng/ml
D3/8 1,172666667 38,07631579
D3/9 1,232 <	  15,6	  ng/ml
D3/10 1,282333333 <15,6	  ng/ml
Table 20. Day 3 results 
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4.5 Electron microscopy results 
 
Electron microscope was used to see if the particles harvested from SNU-216 cells 
were truly exosomes. Indeed, the scanning revealed there were nanovesicles fitting the 
description of exosomes.  
 
 
Figure 33. Negative staining of exosomes harvested from PBS treated SNU-216 cells. The 
vesicles inside boxes are exosomes. (Picture by Mark Barok)  
 
 
Figure 34. Immunostaining of exosomes harvested from trastuzumab-treated SNU-216 
cells. (Picture by Mark Barok) 
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This sample was immunostained with anti-CD63 antibody, then with the gold conjugat-
ed secondary antibody. The dots seen in the surface of the vesicle are from the gold-
bound secondary antibody.  
 
5 Discussion 
 
5.1 Permissions and contracts 
 
Thesis topics realized in the Finnish health and social services has to have its permis-
sions in check. When dealing directly with patients, theses will need also a permission 
from The National Advisory Board on Social Welfare and Health Care Ethics ETENE. 
The permissions of this project have been taken care of already, since the project has 
already started, and generally research teams in Biomedicum Helsinki have this things 
set. The research permission has been applied for from the University of Helsinki. A 
contract between the research team, the university and me was signed.  
 
5.2 Ethics and morality 
 
There were no contradictions of ethics or morality in this project. There was no patient 
contact whatsoever in this project and no one’s identity was compromised. No animals 
or humans were harmed. The project was purely technical. 
 
Presenting results as they are, without embellishing them to suit better the needs of the 
study is one of the most important ethical guidelines of a biomedical scientist. The re-
sults presented in this thesis are shown just as we got them.  
 
5.3 Thoughts about the project 
 
I started this project with little knowledge about what exosomes are. As the project 
went on, I became to understand how complex was this subject. Even though the sub-
ject itself exosomes is quite old, its only the recent interest on them that has taken this 
field forward. 
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The thesis answered well the scientific questions set in the beginning and more. We 
were able to get crucial data from the experiments done during the execution of this 
thesis. More over, we extracted a lot of exosomes for later use in this project. What 
stroke me the most was how laborious it was to collect and purify exosomes from the 
starting culture. It took several weeks from the first cultivation steps to the final product.  
 
5.4 About the results 
 
The results on the HER2 levels provided us with the information we did not previously 
knew for sure. We had the assumption that the TIME cell did not have any HER2 re-
ceptors in their surface. Surprisingly, we got some T-DM1 binding in the TIME cells, 
which were suppose not to bind T-DM1, as it should not have HER2 receptors at all. 
After doing some research, this was explainable with the neonatal Fc-receptors.  
 
The flow cytometry experiment results on the exosomes collected form the 
PBS/trastuzumab/T-DM1 treated SNU-216 and SKBR3 cells were quite informative 
and gave us some preliminary results on the composition of the exosomes derived 
from the treated cells. It was surprising to see how differently the exosomes were from 
one cell line to another. The experiments proved that exosomes do vary a lot depend-
ing where they were originally secreted from. These experiments will be continued in 
the future by increasing the concentration of trastuzumab/T-DM1 the cells will be ex-
posed to. 
 
To conclude very briefly the results of this thesis regarding to the guiding scientific 
questions asked in chapter 1: 
 
• Is there exosomes in the samples collected from cell cultures? Yes, there was 
exosomes in the samples collected from the cell cultures.  
 
• Is there HER2 expression in exosomes? Yes, the T-DM1- Alexa488- GAHIG 
binding in the flow cytometry experiments proved that. 
 
• Is there T-DM1 on the surface of the exosomes prepared from T-DM1-treated 
cancer cells? Yes, there is, but not as much as it was presumed before testing 
the exosomes. 
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5.5 Reliability of the results 
 
There is a lot of variables in this project, the biggest being cell cultures. We followed 
the different aseptic methods strictly to avoid any kind of contamination. Unfortunately, 
during the moving process of the cell laboratory from one floor to another, we managed 
to possibly get our cells contaminated. This was a major setback and required a lot of 
work to reculture the cells in the amounts we had prior contamination.  
 
On the other hand, this was perhaps also a good thing. We got to start from surely 
clean working areas, cultures and materials. The exosomes extracted during this pro-
ject were all collected after the great cleanup. 
 
Another major variable was centrifuging. The first three steps were mostly uneventful, 
but as soon as we moved to the ultracentrifuge phase, things took a tricky turn. The 
polycarbonate bottles did not survive centrifuging after a couple times of use. They 
would crack badly and spill some of its contents to the rotor. Mostly the pellet formed in 
these tubes was salvageable, but it makes think if it has any effect on the subset of 
exosomes collected from the cracked bottles. 
 
Throughout the different experiments, the strict pipetting protocols were a challenge. 
As always, pipetting mistakes made by humans are not uncommon. Different people 
have different ways of pipetting, and that small difference might interfere with the re-
sults. Only by repeating the experiments, will the results be accurate enough to be pre-
sentable. 
 
5.6 Future 
 
The future of this project is promising. While the experiments answered some ques-
tions on the nature of these exosomes, new ones resurged. Some of the future plans 
will include testing the exosomes on macrophages and eventually even get some exo-
somes derived from patients with T-DM1/trastuzumab treated breast cancer. 
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15/01/2015 
Labeling protocol for flow cytometry measurement of the HER2 level of cells 
 
 
Cells: SKBR-3, SNU-216; TIME 
Primary Ab: TDM1, labeling concentration: 50 ug/ml 
Secondary Ab: Alexa-488-GAHIG (goat anti human IgG) 
 
TDM1 store stock: 20 mg/ml  = 20 000 ug/ml 
labeling cc = 50 ug/ml 
dilution: 400X 
D1=predilution: 50X: 2 ul TDM1 + 198 ul BSA-PBS 
then 6,3 ul prediluted TDM1 + 43,7 ul sample  
 
 
Labeling protocol 
 
1. Remove the supernatant from the bottle containing the cells 
2. Wash cells with 5ml PBS 
3. Add trypsin to the bottle (3 ml trypsin in case of medium size bottles) 
4. Put the bottle back into the thermostat, wait until the cells are up 
5. Add cell culture medium (or 10%-FBS-PBS in case of TIME cells) into the bottles to stop trypsin 
and remove the cells. 
6. Put the cells into 50 ml Falcon tubes 
7. Centrifuge 1100 rpm, 7 min 
8. Remove supernatant, keep the pellet (pellet = cells) 
9. Suspend the cells in 1 ml 2%-BSA-PBS 
10. Add 10 ml PBS and 10 ml 2%-BSA-PBS into the Falcon tube 
11. Centrifuge 1100 rpm, 7 min 
12. Remove supernatant, keep the pellet (pellet = cells) 
13. Suspend the cells in 150 ul 2%-BSA-PBS 
 
 
14. Add 43,7 ul cell suspension into 3 sorter tubes, put the tubes into ice, and keep the cells on ice 
during the whole labeling, use ice cold PBS for washing 
 
Tube 1: background,  
Tube 2: GAHIG background 
Tube 3: sample 
 
15. Tube 1: add 6,3 ul BSA-PBS, incubation: on ice, 20 min 
Tube 2: add 6,3 ul BSA-PBS, incubation: on ice, 20 min 
Tube 3: add 6,3 ul prediluted TDM1, incubation: on ice, 20 min 
 
16. Wash the samples: add 4 ml PBS into the tubes, centrifuge: 4 C, 1100 rpm, 7 min 
17. Discard the supernatant, keep the pellet 
18. Wash the samples: add 4 ml BSA-PBS into the tubes, centrifuge: 4 C, 1100 rpm, 7 min 
19. Discard the supernatant, keep the pellet 
 
 
20. Tube 1: add 1,1 ul BSA-PBS, incubation: on ice, 20 min 
Tube 2: add 1,1 ul Alexa-488 GAHIG, incubation: on ice, 20 min 
Tube 3: add 1,1 ul Alexa-488 GAHIG, incubation: on ice, 20 min 
Appendix 1 
  2 (2) 
 
  
 
After adding the fluorescent dye-conjugated Ab to the cells, keep the samples in a dark place. 
 
21. Wash the samples: add 4 ml PBS into the tubes, centrifuge: 4 C, 1100 rpm, 7 min 
22. Discard the supernatant, keep the pellet 
23. Wash the samples: add 4 ml PBS into the tubes, centrifuge: 4 C, 1100 rpm, 7 min 
24. Discard the supernatant, keep the pellet 
25. Suspend the samples in 250 ul 1%-formaldehyde-PBS 
26. Keep the samples at 4 C, and a dark place. 
 
 
NOTE: The protocol was written by Mark Barok 
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Drug treatment protocol 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Protocol written by Mark Barok) 
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Ultracentrifugation protocol after three first centrifugation steps 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Protocol written by Mark Barok) 
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ANALYSIS OF EXOSOMES BY FACS OF LABELED EXOSOMES BOUND TO 
BEADS (Note: this protocol is from the paper “Isolation and characterization of exosomes from 
cell culture supernatants and biological fluid” by Théry and al.) 
 
 
Materials 
Purified exosomes (Basic Protocol 1, step 12; or Basic Protocol 2, step 8; or Basic Protocol 3) 
3.9-µm latex beads, surfactant-free aldehyde/sulfate, 4% solids (Interfacial Dynamics 12-4000; 
http://www.idclatex.com) 
Phosphate-buffered saline (PBS; APPENDIX 2A) 
PBS/1 M glycine 
PBS/0.5% (w/v) BSA 
Fluorochrome-conjugated primary or secondary antibodies 
Test tube rotator wheel for 1.5-ml microcentrifuge tubes 
Microcentrifuge 
Flow cytometer (e.g., FACScan; BD) 
 
1. To analyze exosomes purified by ultracentrifugation: Incubate 5 µg purified exosomes as 
measured by Bradford assay (Support Protocol 9) with 10 µl latex beads 
15 min at room temperature, in a 1.5-ml microcentrifuge tube. 
A nonspecific adsorption of all exosomal proteins to the latex beads occurs in this step. 
 
2. Add PBS to a final volume of 1 ml, and incubate on a test tube rotator wheel 2 hr at 
room temperature. 
Overnight incubation at 4◦C is also possible. 
 
3. Add 110 µl of 1 M glycine (i.e., 100 mM final), mix gently and let stand on the bench at 
room temperature for 30 min. 
The purpose of this step is to saturate any remaining free binding sites on beads. 
 
4. Microcentrifuge 3 min at 4000 rpm, room temperature. Remove the supernatant and 
discard. 
 
5. Resuspend the bead pellet in 1 ml PBS/0.5% BSA and microcentrifuge 3 min at 4000 
rpm, room temperature. Remove the supernatant and discard. 
If not enough proteins are used to coat beads, the bead pellet may be spread along the 
side of the tube. In this case, resuspend the beads by flushing the side of the tube with 
PBS/0.5% (w/v) BSA; the pellet will become visible after the next centrifugation 
 
6. Resuspend the bead pellet and microcentrifuge as in step 5 to wash two more times. 
 
7. Resuspend beads in 0.5 ml PBS/0.5% BSA. 
 
8. Incubate 10 µl coated beads with 50 µl anti-exosomal protein antibody diluted in 
PBS/0.5% BSA 30 min at 4◦C. 
 
9. Wash twice with 150 μl PBS/0.5% BSA. 
If necessary, incubate with 50 μl secondary antibody diluted in PBS/0.5% BSA 30 min at 
4◦C. Wash twice in PBS/BSA, resuspend in 200 μl of PBS/BSA. 
Use fluorophore-coupled primary antibodies, or noncoupled primary antibodies followed by 
fluorophore-coupled secondary antibodies. Always perform negative-control staining on an-
other 10 μl of beads, using an irrelevant isotype-matched primary antibody. 
When analyzing exosomes purified with antibody-coated beads (Basic Protocol 3), use di-
rectly conjugated fluorescent antibodies for FACS, rather than antibodies requiring a sec-
ondary antibody step. 
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If the fluorescence signal is weak with antibodies specific for abundant exosomal proteins 
(e.g., MHC II on dendritic cell exosomes), try to increase the amount of exosomes and/or de-
crease the amount of beads in step 1. 
 
10. Analyze antibody-stained exosome-coated beads on a flow cytometer. 
Adjust the forward scatter (FSC) and side scatter (SSC) to see both single beads and bead 
doublets. Gate on both single and doublet beads to analyze fluorescence. Compare 
fluorescence obtained with specific antibody and with irrelevant isotype control. 
When performing flow cytometric analysis of exosome-coated Dynal beads it is important 
to be aware that these paramagnetic beads may cause blockages in certain flow 
cytometric instruments. This is due to the use of electro-magnetic valves controlling the 
fluidics of certain instruments. This may present a problem for some instruments including 
BD FACScalibur range and BD FACScanto. The authors have never experienced 
any such problems when using BD FACScan. 
 
 
Labeling protocol 
0
3/07/2014 
Exosomes were prepared from the supernatant of 42 flasks of SKBR-3 cells; 96h incubation 
 
1. 8 ul beads + 5 ul exosomes + glycine + resusp in 200 ul BSA-PBS 
2. 8 ul beads + 5 ul exosomes + glycine + resusp in 195 ul BSA-PBS + 5 ul A647-isotype control 
3. 8 ul beads + 5 ul exosomes + glycine + resusp in 200 ul BSA-PBS + 1,2 ul A488-GAHIG  
4. 8 ul beads + 5 ul exosomes + glycine + resusp in 195 ul BSA-PBS + 5 ul A647-anti-CD63 
5. 8 ul beads + 5 ul exosomes + glycine + resusp in 195 ul BSA-PBS + 5 ul A647-anti-CD63 + resusp in 200 ul 
BSA-PBS + 1,2 ul A488-GAHIG 
6. 8 ul beads + 5 ul exosomes + glycine + resusp in 175 ul BSA-PBS + 25 ul TDM1 + resusp in 200 ul BSA-
PBS + 1,2 ul A488-GAHIG 
7. 8 ul beads + 5 ul exosomes + glycine + resusp in 170 ul BSA-PBS + (5 ul A647-anti-CD63 + 25 ul TDM1) + resusp 
in 200 ul BSA-PBS + 1,2 ul A488-GAHIG 
 
 
TDM1 store stock: 20 mg/ml  = 20 000 ug/ml 
labeling cc = 50 ug/ml 
dilution: 400X 
D1=predilution: 50X: 1 ul TDM1 + 49 ul BSA-PBS 
then 25 ul prediluted TDM1 + 175 ul sample  
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T-DM1 quantity assay ultracentrifugation protocol 
 
	  
1.	  day	  
	  
	   	   	  TDM1	  concentration:	  10	  ug/ml	   	  	  
	  	   Add	  10	  ml	  PBS	  into	  a	  UC	  tube	   	  	  
	  	   Add	  5	  ul	  TDM1	  in	  to	  10	  ml	   Sample	  1	  
	  	   Do	  the	  1.	  UC	   	  	  
	  	  
Take	  100	  ul	  sample	  from	  the	  superna-­‐
tant	   Sample	  2	  
	  	   Discard	  the	  supernatant	   	  	  
	  	   Resuspend	  in	  10	  ml	  PBS	   	  	  
	  	   Take	  100	  ul	  sample	   Sample	  3	  
	  	   Do	  the	  2.	  UC	   	  	  
	  	  
Take	  100	  ul	  sample	  from	  the	  superna-­‐
tant	   Sample	  4	  
	  	   Discard	  the	  supernatant	   	  	  
	  	   Resuspend	  in	  10	  ml	  PBS	   Samle	  5	  
	  	   Store	  the	  samples	  at	  -­‐	  80	  C	   	  	  
	   	   	  
	   	   	  
TDM1	  concentration:	  1	  ug/ml	   	  	  
	  	   Add	  10	  ml	  PBS	  into	  a	  UC	  tube	   	  	  
	  	   Add	  0,5	  ul	  TDM1	  in	  to	  10	  ml	   Sample	  6	  
	  	   Do	  the	  1.	  UC	   	  	  
	  	   Take	  100	  ul	  sample	  from	  the	  superna-­‐tant	   Sample	  7	  
	  	   Discard	  the	  supernatant	   	  	  
	  	   Resuspend	  in	  10	  ml	  PBS	   	  	  
	  	   Take	  100	  ul	  sample	   Sample	  8	  
	  	   Do	  the	  2.	  UC	   	  	  
	  	  
Take	  100	  ul	  sample	  from	  the	  superna-­‐
tant	   Sample	  9	  
	  	   Discard	  the	  supernatant	   	  	  
	  	   Resuspend	  in	  10	  ml	  PBS	   Samle	  10	  
	  	   Store	  the	  samples	  at	  -­‐	  80	  C	   	  	  
	   	   	  
	   	   	  TDM1	  store	  stock:	  20	  mg/ml	  =	  20	  000	  ug/ml	  
	  D	  =	  20	  000/10=2000	  
	  
	   	   	  
	   	   	  1.	  UC:	  60	  min,	  RPM:	  28800	  
	  2.	  UC:	  60	  min,	  RPM:	  28800	  
	  
Appendix 5 
  2 (5) 
 
  
	  
2.	  day	  
	  
	   	   	  TDM1	  concentration:	  10	  ug/ml	   	  	  
	  	   Add	  10	  ml	  PBS	  into	  a	  UC	  tube	   	  	  
	  	   Add	  5	  ul	  TDM1	  in	  to	  10	  ml	   Sample	  1	  
	  	   Do	  the	  1.	  UC	   	  	  
	  	  
Take	  100	  ul	  sample	  from	  the	  superna-­‐
tant	   Sample	  2	  
	  	   Discard	  the	  supernatant	   	  	  
	  	   Resuspend	  in	  10	  ml	  PBS	   	  	  
	  	   Take	  100	  ul	  sample	   Sample	  3	  
	  	   Do	  the	  2.	  UC	   	  	  
	  	  
Take	  100	  ul	  sample	  from	  the	  superna-­‐
tant	   Sample	  4	  
	  	   Discard	  the	  supernatant	   	  	  
	  	   Resuspend	  in	  100	  ul	  PBS	   Samle	  5	  
	  	   Store	  the	  samples	  at	  -­‐	  80	  C	   	  	  
	   	   	  
	   	   	  
TDM1	  concentration:	  1	  ug/ml	   	  	  
	  	   Add	  10	  ml	  PBS	  into	  a	  UC	  tube	   	  	  
	  	   Add	  0,5	  ul	  TDM1	  in	  to	  10	  ml	   Sample	  6	  
	  	   Do	  the	  1.	  UC	   	  	  
	  	   Take	  100	  ul	  sample	  from	  the	  superna-­‐tant	   Sample	  7	  
	  	   Discard	  the	  supernatant	   	  	  
	  	   Resuspend	  in	  10	  ml	  PBS	   	  	  
	  	   Take	  100	  ul	  sample	   Sample	  8	  
	  	   Do	  the	  2.	  UC	   	  	  
	  	  
Take	  100	  ul	  sample	  from	  the	  superna-­‐
tant	   Sample	  9	  
	  	   Discard	  the	  supernatant	   	  	  
	  	   Resuspend	  in	  100	  ul	  PBS	   Samle	  10	  
	  	   Store	  the	  samples	  at	  -­‐	  80	  C	   	  	  
	   	   	  
	   	   	  TDM1	  store	  stock:	  20	  mg/ml	  =	  20	  000	  ug/ml	  
	  D	  =	  20	  000/10=2000	  
	  
	   	   	  
	   	   	  1.	  UC:	  100	  min,	  RPM:	  28800	  
	  2.	  UC:	  75	  min,	  RPM:	  28800	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   Dilution	   	  	  
Sample1	   10	  ug/ml	  
10	  000	  
ng/ml	   40	  
250	  
ng/ml	  
	  	   	   	   	   	  	  
Sample	  
6	   1	  ug/ml	  
1	  000	  
ng/ml	   4	  
250	  
ng/ml	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3.	  day	  
	  
	  
	   	   	  
	  
TDM1	  concentration:	  10	  ug/ml	   	  	   	  
	  	   Add	  4997,5	  ul	  PBS	  into	  a	  UC	  tube	   	  	   	  
	  	   Add	  2,5	  ul	  TDM1	  in	  to	  10	  ml	   Sample	  1	   	  
	  	   Do	  the	  1.	  UC	   	  	   	  
	  	  
Take	  100	  ul	  sample	  from	  the	  superna-­‐
tant	   Sample	  2	   	  
	  	   Discard	  the	  supernatant	   	  	   	  
	  	   Resuspend	  in	  10	  ml	  PBS	   	  	   	  
	  	   Take	  100	  ul	  sample	   Sample	  3	   	  
	  	   Do	  the	  2.	  UC	   	  	   	  
	  	  
Take	  100	  ul	  sample	  from	  the	  superna-­‐
tant	   Sample	  4	   	  
	  	   Discard	  the	  supernatant	   	  	   	  
	  	   Resuspend	  in	  100	  ul	  PBS	   Samle	  5	   	  
	  	   Store	  the	  samples	  at	  -­‐	  80	  C	   	  	   	  
	   	   	  
	  
	   	   	   	  
TDM1	  concentration:	  50	  ug/ml	   	  	   	  
	  	   Add	  4987,5	  ul	  PBS	  into	  a	  UC	  tube	   	  	   	  
	  	   Add	  12,5	  ul	  TDM1	  in	  to	  10	  ml	   Sample	  6	   	  
	  	   Do	  the	  1.	  UC	   	  	   	  
	  	   Take	  100	  ul	  sample	  from	  the	  superna-­‐tant	   Sample	  7	   	  
	  	   Discard	  the	  supernatant	   	  	   	  
	  	   Resuspend	  in	  10	  ml	  PBS	   	  	   	  
	  	   Take	  100	  ul	  sample	   Sample	  8	   	  
	  	   Do	  the	  2.	  UC	   	  	   	  
	  	  
Take	  100	  ul	  sample	  from	  the	  superna-­‐
tant	   Sample	  9	   	  
	  	   Discard	  the	  supernatant	   	  	   	  
	  	   Resuspend	  in	  100	  ul	  PBS	   Samle	  10	   	  
	  	   Store	  the	  samples	  at	  -­‐	  80	  C	   	  	   	  
	   	   	  
	  
	   	   	  
	  
TDM1	  store	  stock:	  20	  mg/ml	  =	  20	  000	  ug/ml	  
	  
	  
D	  =	  20	  000/10=2000	  
	  
	  
	   	   	  
	  
	   	   	  
	  
1.	  UC:	  100	  min,	  RPM:	  28800	  
	  
	  
2.	  UC:	  75	  min,	  RPM:	  28800	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   Dilution	   	  	  
10	  
ug/ml	   10	  000	  ng/ml	   50	   200	  ng/ml	  
	  	   	   	   	  	  
50	  
ug/ml	   50	  000	  ng/ml	   200	   250	  ng/ml	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